Foreign direct investment in Indian pharma sector causing concern
The spate of mergers and acquisitions (M&As) in the Indian pharma sector continues unabated. As foreign players continue to scout for potential Indian targets to complement their existing offerings and provide a platform for incremental growth, the bogey of drug multinational companies (MNCs) attacking India's ability to produce low-cost quality generic drugs has once again come to the fore, reports The Pharma Letter’s India correspondent.
As domestic private equity major ChrysCapital is set to pick up a 10% stake in Mankind Pharmaceuticals, with GIC of Singapore and CPPIB of Canada, for $350 million, the UK’s AstraZeneca has announced its plans to invest $90 million in India over the next five years.
Fosun International, the Chinese conglomerate known to be aggressive on the international M&A circuit, is the latest entrant to join a bidding war to take control of India's second largest healthcare provider, Fortis Healthcare.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze